Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px
Product › Details

Vitrakvi®

Products Next higher product group larotrectinib (LOXO-101)
Period Status 2018-11-26 registration start
Organisation Organisation Loxo Oncology Inc. (Nasdaq: LOXO)
Document Source Bayer Corporation. (11/26/18). "Press Release: FDA Approves Vitrakvi (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion". Whippany, NJ & Stamford, CT.
     

   
Record changed: 2019-06-04

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px

More documents for larotrectinib (LOXO-101)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x113px




» top